SCHEMBL13495403

SCHEMBL13495403

CON1C(=O)c2cc3cccnc3cc2C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.50
PDGFRA P16234 1/20 0.50
HTT P42858 3/20 0.43
ALOX15 P16050 1/20 0.43
POLB P06746 2/20 0.43
TP53 P04637 2/20 0.43
PSMD14 O00487 1/20 0.43
MMP2 P08253 1/20 0.43
ALDH1A1 P00352 7/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
CASP6 P55212 1/20 0.38
CASP1 P29466 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CASP7 P55210 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
NR4A2 P43354 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13495401 0.79 MAOA (0.43) HTTALDH1A1MEN1KMT2ACYP1A2
SCHEMBL13495404 0.76 MAOA (0.41) HTTALDH1A1MEN1KMT2ACYP1A2
SCHEMBL13495402 0.75 CYP2D6 (0.50) HTTTP53ALDH1A1MEN1KMT2A
SCHEMBL14560549 0.74 ALDH1A1 (0.46) PDGFRBPDGFRAHTTPOLBTP53
SCHEMBL9308045 0.73 NPC1 (0.47) PDGFRBPDGFRAHTTALOX15POLB
SCHEMBL5393255 0.71 POLB (0.46) PDGFRBPDGFRAHTTPOLBTP53
SCHEMBL20062355 0.70 ALDH1A1 (0.54) PDGFRBPDGFRAHTTALOX15POLB
SCHEMBL29350099 0.69 NPC1 (0.65) PDGFRBPDGFRAHTTALOX15POLB
SCHEMBL150476 0.69 NPC1 (0.65) PDGFRBPDGFRAHTTALOX15POLB
SCHEMBL798345 0.67 GAA (0.52) HTTALOX15POLBTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC PDGFRB 2653/4885PDGFRA 1542/4885HTT 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.